- Home
- UROY vs CMPS Comparison
UROY vs CMPS Comparison
Compare UROY & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UROY
- CMPS
- Stock Information
- Founded
- UROY 2017
- CMPS 2020
- Country
- UROY Canada
- CMPS United Kingdom
- Employees
- UROY N/A
- CMPS N/A
- Industry
- UROY
- CMPS Biotechnology: Pharmaceutical Preparations
- Sector
- UROY
- CMPS Health Care
- Exchange
- UROY Nasdaq
- CMPS Nasdaq
- Market Cap
- UROY 294.0M
- CMPS 280.2M
- IPO Year
- UROY N/A
- CMPS 2020
- Fundamental
- Price
- UROY $2.13
- CMPS $4.03
- Analyst Decision
- UROY Strong Buy
- CMPS Strong Buy
- Analyst Count
- UROY 2
- CMPS 6
- Target Price
- UROY $5.60
- CMPS $33.60
- AVG Volume (30 Days)
- UROY 2.4M
- CMPS 666.3K
- Earning Date
- UROY 12-12-2024
- CMPS 10-31-2024
- Dividend Yield
- UROY N/A
- CMPS N/A
- EPS Growth
- UROY 256.61
- CMPS N/A
- EPS
- UROY 0.03
- CMPS N/A
- Revenue
- UROY $27,478,292.00
- CMPS N/A
- Revenue This Year
- UROY N/A
- CMPS N/A
- Revenue Next Year
- UROY $72.53
- CMPS N/A
- P/E Ratio
- UROY $83.69
- CMPS N/A
- Revenue Growth
- UROY 31.26
- CMPS N/A
- 52 Week Low
- UROY $1.86
- CMPS $3.86
- 52 Week High
- UROY $3.76
- CMPS $12.75
- Technical
- Relative Strength Index (RSI)
- UROY 33.80
- CMPS 37.75
- Support Level
- UROY $2.06
- CMPS $3.86
- Resistance Level
- UROY $2.70
- CMPS $4.20
- Average True Range (ATR)
- UROY 0.14
- CMPS 0.29
- MACD
- UROY -0.02
- CMPS 0.00
- Stochastic Oscillator
- UROY 10.94
- CMPS 16.59
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is the investment in a portfolio of uranium interests.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.